MX2016010912A - Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. - Google Patents
Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.Info
- Publication number
- MX2016010912A MX2016010912A MX2016010912A MX2016010912A MX2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A
- Authority
- MX
- Mexico
- Prior art keywords
- novel
- oxazolo
- pyrazine
- dihydro
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención se refiere a nuevos derivados de 6,7-dihidro-3H-oxazolo[3,4-a]pirazina-5,8-diona o a una mezcla de éstos. La presente invención también contempla composiciones farmacéuticas que comprendan una cantidad eficaz de uno de los nuevos compuestos que son objeto de la presente invención, así como el uso de dichos compuestos y/o derivados como inhibidores de enzimas fosfodiesterasas y el uso de los compuestos y/o derivados en el tratamiento de la disfunción eréctil, de trastornos y/o condiciones tratables con relajación de tejidos y de trastornos tratables con inhibidores de fosfodiesterasas, más específicamente con inhibidores de la PDE-5. Un objetivo adicional de la presente invención es proveer un medicamento que comprenda una cantidad terapéuticamente eficaz de uno de los nuevos compuestos y un método de tratamiento utilizando dichos nuevos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943825P | 2014-02-24 | 2014-02-24 | |
PCT/BR2015/000023 WO2015123748A1 (pt) | 2014-02-24 | 2015-02-24 | "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA " |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016010912A true MX2016010912A (es) | 2016-11-30 |
MX369840B MX369840B (es) | 2019-11-22 |
Family
ID=53877456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010912A MX369840B (es) | 2014-02-24 | 2015-02-24 | Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9359378B2 (es) |
EP (1) | EP3133072B1 (es) |
JP (1) | JP6636463B2 (es) |
KR (1) | KR102408431B1 (es) |
AR (1) | AR099523A1 (es) |
AU (1) | AU2015221431B2 (es) |
BR (1) | BR112016019609B1 (es) |
CA (1) | CA2940225C (es) |
CL (1) | CL2016002125A1 (es) |
ES (1) | ES2734063T3 (es) |
HU (1) | HUE044993T2 (es) |
IL (1) | IL247330B (es) |
MX (1) | MX369840B (es) |
PL (1) | PL3133072T3 (es) |
PT (1) | PT3133072T (es) |
TR (1) | TR201910896T4 (es) |
UY (1) | UY36010A (es) |
WO (1) | WO2015123748A1 (es) |
ZA (1) | ZA201606522B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3144770A1 (en) * | 2019-07-15 | 2021-01-21 | Biolab Sanus Farmaceutica Ltda | Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002098877A1 (en) * | 2001-06-05 | 2002-12-12 | Lilly Icos Llc | Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives |
AR045950A1 (es) * | 2003-10-09 | 2005-11-16 | Speedel Experimenta Ag | Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. |
AR073522A1 (es) * | 2008-09-30 | 2010-11-10 | Biolab Sanus Farmaceutica Ltda | Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol |
BRPI0903803B1 (pt) * | 2009-09-30 | 2019-07-09 | Biolab Sanus Farmacêutica Ltda. | Composto, processo de preparação, composição farmacêutica e uso dos compostos |
UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
-
2015
- 2015-02-23 AR ARP150100529A patent/AR099523A1/es active IP Right Grant
- 2015-02-24 WO PCT/BR2015/000023 patent/WO2015123748A1/pt active Application Filing
- 2015-02-24 EP EP15752140.2A patent/EP3133072B1/en active Active
- 2015-02-24 AU AU2015221431A patent/AU2015221431B2/en active Active
- 2015-02-24 KR KR1020167026361A patent/KR102408431B1/ko active IP Right Grant
- 2015-02-24 TR TR2019/10896T patent/TR201910896T4/tr unknown
- 2015-02-24 JP JP2016570147A patent/JP6636463B2/ja active Active
- 2015-02-24 US US14/630,410 patent/US9359378B2/en active Active
- 2015-02-24 PT PT15752140T patent/PT3133072T/pt unknown
- 2015-02-24 ES ES15752140T patent/ES2734063T3/es active Active
- 2015-02-24 PL PL15752140T patent/PL3133072T3/pl unknown
- 2015-02-24 UY UY0001036010A patent/UY36010A/es active IP Right Grant
- 2015-02-24 MX MX2016010912A patent/MX369840B/es active IP Right Grant
- 2015-02-24 HU HUE15752140 patent/HUE044993T2/hu unknown
- 2015-02-24 CA CA2940225A patent/CA2940225C/en active Active
- 2015-02-24 BR BR112016019609-0A patent/BR112016019609B1/pt active IP Right Grant
-
2016
- 2016-08-17 IL IL247330A patent/IL247330B/en active IP Right Grant
- 2016-08-23 CL CL2016002125A patent/CL2016002125A1/es unknown
- 2016-09-21 ZA ZA2016/06522A patent/ZA201606522B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2940225C (en) | 2021-12-28 |
KR102408431B1 (ko) | 2022-06-13 |
BR112016019609B1 (pt) | 2022-06-14 |
ZA201606522B (en) | 2018-04-25 |
WO2015123748A1 (pt) | 2015-08-27 |
US9359378B2 (en) | 2016-06-07 |
US20150239903A1 (en) | 2015-08-27 |
IL247330A0 (en) | 2016-09-29 |
AU2015221431A8 (en) | 2016-11-24 |
AU2015221431A1 (en) | 2016-09-29 |
EP3133072A4 (en) | 2017-08-09 |
AR099523A1 (es) | 2016-07-27 |
PL3133072T3 (pl) | 2019-10-31 |
EP3133072A1 (en) | 2017-02-22 |
CA2940225A1 (en) | 2015-08-27 |
JP6636463B2 (ja) | 2020-01-29 |
TR201910896T4 (tr) | 2019-08-21 |
PT3133072T (pt) | 2019-07-26 |
AU2015221431B2 (en) | 2018-04-19 |
BR112016019609A2 (es) | 2017-08-22 |
IL247330B (en) | 2020-10-29 |
UY36010A (es) | 2015-09-30 |
MX369840B (es) | 2019-11-22 |
CL2016002125A1 (es) | 2016-12-30 |
JP2017506263A (ja) | 2017-03-02 |
HUE044993T2 (hu) | 2019-11-28 |
KR20160116028A (ko) | 2016-10-06 |
ES2734063T3 (es) | 2019-12-04 |
EP3133072B1 (en) | 2019-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MY193524A (en) | Diaryl macrocycles as modulators of protein kinases | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
PH12017502260A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
CL2013000434A1 (es) | Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |